CD93/C1qR (E5H9B) Rabbit mAb #55011
- WB
- IP
- IHC
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 120, 82 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:800 - 1:3200 |
| Flow Cytometry (Live) | 1:400 - 1:1600 |
Storage
For a carrier free (BSA and azide free) version of this product see product #55570.
Protocol
Specificity / Sensitivity
CD93/C1qR (E5H9B) Rabbit mAb recognizes endogenous levels of total CD93/C1qR protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human CD93/C1qR protein.
Background
CD93/complement component C1q receptor (C1qR) is a type-I transmembrane glycoprotein belonging to the CLEC14 family of surface antigens, which share a similar ectodomain architecture highlighted by the presence of a C-type lectin domain and multiple EGF-like domains. CD93/C1qR expression is primarily restricted to endothelial cells associated with normal and tumor-associated vasculature as well as immune cells of the myeloid lineage, including monocytes and neutrophils (1). The extracellular domain of CD93/C1qR is rich in O-linked glycosylation modifications, which stabilizes its surface expression by protecting it from proteolytic cleavage (2,3). CD93/C1qR regulates various aspects of endothelial cell biology, including proliferation, migration, and adhesion (4). Indeed, research studies have demonstrated that surface expressed CD93/C1qR binds to an endothelial specific extracellular matrix ligand, multimerin-2, and disrupting the interaction compromises angiogenesis (5). Furthermore, CD93 expression is upregulated in tumor vasculature and correlates with poor survival (6-8).
- Nepomuceno, R.R. and Tenner, A.J. (1998) J Immunol 160, 1929-35.
- Park, M. and Tenner, A.J. (2003) J Cell Physiol 196, 512-22.
- Ikewaki, N. et al. (2013) Microbiol Immunol 57, 822-32.
- Orlandini, M. et al. (2014) Oncotarget 5, 2750-60.
- Khan, K.A. et al. (2017) Oncogene 36, 6097-6108.
- Bao, L. et al. (2016) Biochem Biophys Res Commun 476, 467-474.
- Langenkamp, E. et al. (2015) Cancer Res 75, 4504-16.
- Sun, Y. et al. (2021) Sci Transl Med 13, eabc8922. doi: 10.1126/scitranslmed.abc8922.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.